Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 36.57

From 52W high−53.77%

Volume4.26M

Market capCNY 13.67B

P/E (TTM)19.6x

P/S (TTM)4.9x

Div yield4.71%

Key dataSep 18, 2026

Open

CNY 36.57

From 52W high

−53.77%

Volume

4.26M

Market cap

CNY 13.67B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.3x

P/E (TTM)

19.6x

RSI (14)

35.8

MomentumView details →

1D Return

−3.09%

YTD Return

−48.61%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

19.6x

EV/EBITDA

13.3x

EV/Sales

4.7x

P/S (TTM)

4.9x

P/B (TTM)

7.4x

ProfitabilityView details →

Gross Margin

81.60%

Net Margin

28.87%

EBITDA Margin

35.43%

ROE (TTM)

34.62%

ROA (TTM)

27.52%

Asset Turnover

0.99x

GrowthView details →

Revenue YoY

+23.03%

EPS YoY

+68.31%

FCF YoY

+59.84%

Revenue CAGR 3Y

+25.54%

EPS CAGR 3Y

+18.06%

EBITDA YoY

—

MomentumView details →

1D Return

−3.09%

YTD Return

−48.61%

1Y Return

−47.29%

RSI (14)

35.8

vs 50D SMA

−9.49%

vs 200D SMA

−36.84%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

2.23x

Quick Ratio

1.81x

Div Yield

4.71%

Div Rate

CNY 1.70

Div Growth 1Y

−43.44%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.62B

Net Income (TTM)

756.37M

Op. CF (TTM)

771.21M

Latest newsMore news →

Shenyang Xingqi Pharmaceutical received a drug clinical trial approval notice from China's National Medical Products Administration for its SQ-25012 injection, allowing clinical trials for treating thyroid eye disease.6d ago

Similar companies

江苏雷利300660.SZ 嘉美包装002969.SZ 大北农002385.SZ 赢合科技300457.SZ 上峰材料000672.SZ 利亚德300296.SZ Find similar companies →

Latest newsMore news →

Shenyang Xingqi Pharmaceutical received a drug clinical trial approval notice from China's National Medical Products Administration for its SQ-25012 injection, allowing clinical trials for treating thyroid eye disease.6d ago